

[StatLab launches PiSmart S1 slide printer](#)

written by CAP TODAY
September 17, 2025

Sept. 17, 2025—StatLab Medical Products has launched the PiSmart S1 single hopper slide printer.



©2026 CAP TODAY, all rights reserved.

[C2N launches RUO blood tests for Alzheimer's disease](#)

written by CAP TODAY
September 17, 2025

September 2025—C2N Diagnostics has launched two plasma assays for research use only. C2N eMTBR-tau243 (endogenous microtubule binding region) is a blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer's disease. The assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by the company nearly two years ago. C2N obtained exclusive rights for these technologies from the Bateman Lab at WashU Medicine, St. Louis, Mo. The company plans to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future.



©2026 CAP TODAY, all rights reserved.

[Proscia releases laboratory leadership report](#)

written by CAP TODAY
September 17, 2025

September 2025—Proscia partnered with the Dark Intelligence Group to survey more than 360 senior professionals representing independent, hospital, and academic laboratories and published a report on the findings. The “2025 Laboratory Leadership Report: Insights on Digital Pathology, AI, and Precision Medicine” finds that 38 percent of laboratory leaders cite staffing shortages as their biggest challenge and 31 percent cite declining reimbursement as their top concern. The top-ranked opportunities for labs are automation to drive efficiency (30 percent), molecular and genetic testing (29 percent), and artificial intelligence (25 percent).



©2026 CAP TODAY, all rights reserved.

[FDA approves Oncomine Dx Express for Zegfrovy](#)

written by CAP TODAY
September 17, 2025

September 2025—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Express test, an in vitro diagnostic assay, for use as a companion diagnostic for Dical’s Zegfrovy (sunvozertinib) to identify patients with non-small cell lung cancer harboring *EGFR* exon 20 insertion mutations. In addition, the test has been approved for tumor profiling in solid tumors and detects cancer mutations with evidence of clinical significance and potential clinical significance across 46 genes.



©2026 CAP TODAY, all rights reserved.

[Quest introduces testing for Oropouche virus](#)

written by CAP TODAY
September 17, 2025

September 2025—Quest Diagnostics has launched a diagnostic laboratory test for the Oropouche virus, an emerging virus in the Americas that is spread to people by infected biting midges and some species of mosquitoes. The viral disease presents clinically with symptoms that overlap with those of other arboviral diseases such as Dengue, Zika, and chikungunya. Quest's laboratory in San Juan Capistrano, Calif., will perform the test using PCR technology, with serology testing to follow later this quarter.



©2026 CAP TODAY, all rights reserved.

[Qiagen expands portfolio for MRD testing with strategic partnerships](#)

written by CAP TODAY
September 17, 2025

September 2025—Qiagen is expanding its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease testing in clinical trials to support pharma co-development projects for companion diagnostics. Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with Qiagen to create companion diagnostics for MRD testing in solid tumors. The assays, for use on the QIAcuity digital PCR platform, are designed to enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity.



©2026 CAP TODAY, all rights reserved.

Agilent expands Dako Omnis family

written by CAP TODAY
September 17, 2025

September 2025—Agilent Technologies is introducing three models to its Dako Omnis family of instruments—the Omnis 110, 165, and 165 Duo—designed to provide laboratories with the flexibility to tailor staining solutions according to volume, workflow, and diagnostic requirements. The Dako Omnis 110 is for low- to medium-volume labs and delivers up to 110 immunohistochemistry slides per day. The Dako Omnis 165 is engineered for medium-high volume labs and has a throughput of up to 165 IHC slides per day, and the 165 Duo has the capacity to run IHC and in situ hybridization slides. All models feature continuous, case-based processing and shared reagents. A newly integrated direct connection for deionized water and nonhazardous waste reduces handling time.



©2026 CAP TODAY, all rights reserved.

Bruker MALDI Biotyper systems awarded ACT label

written by CAP TODAY
September 17, 2025

September 2025—Bruker's MALDI Biotyper Sirius and Sirius One systems have been awarded the My Green Lab ACT Ecolabel. The MALDI Biotyper systems for microbial identification received an Environmental Impact Factor score of 26.8 (EU and U.K.) and 35.4 (United States).



©2026 CAP TODAY, all rights reserved.

illumina launches TruSight Oncology 500 v2 research assay

written by CAP TODAY
September 17, 2025

September 2025—Illumina has launched TruSight Oncology 500 version 2, the next generation of the company's flagship pancancer next-generation sequencing assay that enables in-house comprehensive genomic profiling from formalin-fixed, paraffin-embedded tissue for oncology research. A key enhancement of the new assay is fully integrated homologous recombination deficiency analysis included for every sample, powered by a gold-standard genomic instability scoring algorithm licensed from Myriad Genetics. Other updates include more sensitive variant calling and improved coverage of difficult genomic regions. The new kit has 50 percent less packaging and 70 percent fewer tubes.



©2026 CAP TODAY, all rights reserved.

New England Biolabs launches NEBNext library prep kit

written by CAP TODAY
September 17, 2025

September 2025—New England Biolabs launched the NEBNext Low-bias Small RNA library prep kit, designed to minimize biased representation of small RNA species in sequencing data. A novel splint adaptor increases the diversity of interactions, facilitating ligation and increasing sensitivity, with a streamlined, simplified protocol. As a result, researchers can analyze all RNA species present in biologically relevant samples. Standard and 2'-O-methylated samples can also be processed using the same protocol, with multiplexing enabled through up to 480 compatible unique dual index primer pairs (available separately). Total workflow time is approximately 3.5 hours and the shelf life is 18 months.



©2026 CAP TODAY, all rights reserved.